-
Wells Fargo's Analyst Discusses Valeant's 'Apology Tour'
Wednesday, April 27, 2016 - 2:58pm | 346David Maris is an analyst at Wells Fargo that initiated coverage of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) with a Sell rating back in February. On Wednesday, he was a guest on CNBC's Halftime Report segment to discuss his views on the company. Maris began by saying that appointing Joe Pappa...